CN114249665B - 一种左卡尼汀原料药制备方法 - Google Patents
一种左卡尼汀原料药制备方法 Download PDFInfo
- Publication number
- CN114249665B CN114249665B CN202111483528.5A CN202111483528A CN114249665B CN 114249665 B CN114249665 B CN 114249665B CN 202111483528 A CN202111483528 A CN 202111483528A CN 114249665 B CN114249665 B CN 114249665B
- Authority
- CN
- China
- Prior art keywords
- levocarnitine
- filtering
- filtrate
- product
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 54
- 229960001518 levocarnitine Drugs 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000001914 filtration Methods 0.000 claims abstract description 39
- 239000000706 filtrate Substances 0.000 claims abstract description 36
- 239000000047 product Substances 0.000 claims abstract description 36
- 238000003756 stirring Methods 0.000 claims abstract description 27
- 238000004090 dissolution Methods 0.000 claims abstract description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000001694 spray drying Methods 0.000 claims abstract description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004965 Silica aerogel Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 11
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 11
- 239000008367 deionised water Substances 0.000 claims abstract description 10
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 10
- 238000004042 decolorization Methods 0.000 claims abstract description 9
- 239000003480 eluent Substances 0.000 claims abstract description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 20
- 239000012065 filter cake Substances 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 14
- 239000012535 impurity Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012466 permeate Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003760 magnetic stirring Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010058892 Carnitine deficiency Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GPEHQHXBPDGGDP-UHFFFAOYSA-N acetonitrile;propan-2-one Chemical compound CC#N.CC(C)=O GPEHQHXBPDGGDP-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- VZHHNBNSMNNUAD-UHFFFAOYSA-N cobalt 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound [Co].OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VZHHNBNSMNNUAD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910021423 nanocrystalline silicon Inorganic materials 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
旋光度[a]D20 | 光学纯度(P) | 收率(%) | 杂质A量 | |
实施例1 | -30.98 | 99.94% | 92.01% | <0.01% |
实施例2 | -30.88 | 99.63% | 92.3% | <0.02% |
实施例3 | -30.89 | 99.63% | 93.14% | <0.01% |
实施例4 | -30.10 | 97.10% | 90.34% | <0.03% |
实施例5 | -30.00 | 96.79% | 93.3% | <0.03% |
实施例6 | -30.55 | 98.54% | 91.22% | <0.01% |
对照例1 | -27.54 | 88.83% | 87.28% | >0.07% |
对照例2 | -27.11 | 87.45% | 92.67% | >0.06% |
对照例3 | -27.21 | 87.77% | 91.98% | >0.06% |
对照例4 | -28.01 | 90.35% | 91.65% | >0.06% |
对照例5 | -27.98 | 90.25% | 80.76% | <0.03% |
外观(压片后) | 吸湿性(平衡时间) | |
实施例1 | 色泽均匀,无分层 | 115s |
实施例2 | 色泽均匀,无分层 | 105s |
实施例3 | 色泽均匀,无分层 | 110s |
实施例4 | 有微量色差,无分层 | 78s |
实施例5 | 有微量色差,无分层 | 15s |
实施例6 | 色泽均匀,无分层 | 68s |
对照例1 | 有色差,无分层 | 19s |
对照例2 | 有色差,无分层 | 30s |
对照例3 | 有色差,有分层 | 71s |
对照例4 | 色泽均匀,有分层 | 12s |
对照例5 | 有分层现象,色泽均匀 | 89s |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111483528.5A CN114249665B (zh) | 2021-12-07 | 2021-12-07 | 一种左卡尼汀原料药制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111483528.5A CN114249665B (zh) | 2021-12-07 | 2021-12-07 | 一种左卡尼汀原料药制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114249665A CN114249665A (zh) | 2022-03-29 |
CN114249665B true CN114249665B (zh) | 2024-01-23 |
Family
ID=80794104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111483528.5A Active CN114249665B (zh) | 2021-12-07 | 2021-12-07 | 一种左卡尼汀原料药制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114249665B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009102263A (ja) * | 2007-10-24 | 2009-05-14 | Mitsubishi Rayon Co Ltd | L−カルニチンの単離精製方法 |
CN102351722A (zh) * | 2011-08-10 | 2012-02-15 | 江西新先锋医药有限公司 | 一种左卡尼汀化合物及其组合物 |
CN102367227A (zh) * | 2011-08-26 | 2012-03-07 | 贺金凤 | 一种更为稳定的左卡尼汀化合物及其药物组合物 |
CN109053479A (zh) * | 2018-10-15 | 2018-12-21 | 兆科药业(合肥)有限公司 | 一种季胺内盐的合成方法 |
CN111233686A (zh) * | 2019-12-24 | 2020-06-05 | 常州寅盛药业有限公司 | 一种左卡尼汀重结晶的方法 |
CN111253270A (zh) * | 2019-12-24 | 2020-06-09 | 常州寅盛药业有限公司 | 一种左卡尼汀脱盐的方法 |
-
2021
- 2021-12-07 CN CN202111483528.5A patent/CN114249665B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009102263A (ja) * | 2007-10-24 | 2009-05-14 | Mitsubishi Rayon Co Ltd | L−カルニチンの単離精製方法 |
CN102351722A (zh) * | 2011-08-10 | 2012-02-15 | 江西新先锋医药有限公司 | 一种左卡尼汀化合物及其组合物 |
CN102367227A (zh) * | 2011-08-26 | 2012-03-07 | 贺金凤 | 一种更为稳定的左卡尼汀化合物及其药物组合物 |
CN109053479A (zh) * | 2018-10-15 | 2018-12-21 | 兆科药业(合肥)有限公司 | 一种季胺内盐的合成方法 |
CN111233686A (zh) * | 2019-12-24 | 2020-06-05 | 常州寅盛药业有限公司 | 一种左卡尼汀重结晶的方法 |
CN111253270A (zh) * | 2019-12-24 | 2020-06-09 | 常州寅盛药业有限公司 | 一种左卡尼汀脱盐的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114249665A (zh) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102659818B (zh) | 一种盐酸头孢替安晶体化合物及其制备方法及含该化合物的药物组合物 | |
CN103864819B (zh) | 一种头孢他啶化合物及其药物组合物 | |
CN101095670B (zh) | 木犀草素磷脂复合物及其制备方法和应用 | |
CN104876947B (zh) | 盐酸头孢他美酯水合物晶体及其分散片 | |
CN102813651A (zh) | 一种含埃索美拉唑钠的药物组合物及其制备方法 | |
CN110652975B (zh) | 一种(s)-binol衍生物csp填料及其制备方法和应用 | |
CN114249665B (zh) | 一种左卡尼汀原料药制备方法 | |
CN109721632A (zh) | 一种高纯度神经节苷脂gm1及其制备方法 | |
CN111454271B (zh) | 一种吡咯烷羧酸类化合物的钠盐、结晶形式及其制备方法 | |
CN103183587B (zh) | 3,3’,5,5’-四异丙基-4,4’-二联苯酚的新晶型及其制备方法 | |
CN102276630A (zh) | 一种头孢米诺钠结晶化合物及其组合物粉针 | |
WO2014036865A1 (zh) | 芬戈莫德粘酸盐及其晶体的制备方法和用途 | |
CN111978266B (zh) | 一种帕瑞昔布钠、注射制剂及制备方法 | |
CN102351722B (zh) | 一种左卡尼汀化合物及其组合物 | |
CN103304597A (zh) | 一种磷酸肌酸钠化合物,其制备方法及其药物组合物及制备方法 | |
WO2009155756A1 (zh) | 巴戟天中药材或其提取物中巴戟天寡糖的含量测定方法 | |
CN102050846B (zh) | 一种胺基糖及其制备方法和用途 | |
CN103284975B (zh) | 一种盐酸二甲双胍肠溶胶囊及其制备方法 | |
CN105985252B (zh) | 一种门冬氨酸鸟氨酸晶型iv及其制备方法 | |
CN109942487A (zh) | 一种吡啶类化合物及其制备方法、用途 | |
CN109232279B (zh) | 一种钆塞酸二钠中间体的纯化方法 | |
CN104490798B (zh) | 无结晶水二丁酰环磷腺苷钙晶型冻干粉针及其制备方法 | |
CN113527223B (zh) | 一种钆布醇的精制方法 | |
CN109400606B (zh) | 一种从阿哌沙班粗品中精制阿哌沙班的方法 | |
CN103724359B (zh) | 一种无定形头孢替坦酸及由其制备头孢替坦二钠的方法和含有该头孢替坦二钠的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240118 Address after: No. 58 Xiahong Road, High tech Industrial Development Zone, Anqing City, Anhui Province, 246002 Applicant after: Anhui Puli Pharmaceutical Co.,Ltd. Address before: 246000 No. 58, xiahong Road, high tech Industrial Development Zone, Anqing City, Anhui Province Applicant before: Anhui Puli Pharmaceutical Co.,Ltd. Applicant before: HAINAN POLY PHARM. Co.,Ltd. Applicant before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. |